title: Plasmatic homocysteine concentration and its relationship with complications associated to diabetes mellitus.
abstract: METHODS
  In the search for new factors of cardiovascular risk associated to diabetes mellitus (DM), special attention has been paid in recent years to hyperhomocysteinaemia. Therefore, we have established the concentration of homocysteine (Hcy) and other biochemical parameters in the plasma of a group of 57 type 1 and 32 type 2 diabetic patients and 54 control subjects and studied whether plasmatic homocysteinaemia was related to macroangiopathy, nephropathy, retinopathy and neuropathy. Because of significant differences for plasma Hcy values between men and women in the control group, we distinguished between both groups throughout the study.
  
  
  RESULTS
  Patients with DM had higher Hcy than control subjects (11.7+/-5.4 vs. 10.1+/-2.4 micromol/l, p<0.05). Fasting hyperhomocysteinaemia was considered as the mean of the plasma Hcy for control subjects+2 SD (14.9 micromol/l in total group, 15.6 micromol/l in males and 13.9 micromol/l in females). In the studied groups with complications, we found significant differences between normohomocysteinaemic type 1 diabetic patients and those considered hyperhomocysteinaemic by us. On the other hand, patients having type 1 DM and complications had higher plasmatic Hcy concentration than those with no complications.
  
  
  CONCLUSIONS
  We have found a relationship between high Hcy levels and prevalence of macroangiopathy, retinopathy and nephropathy in the type 1 diabetic patients, which was not been observed in the type 2 diabetic patients of our study. As a result, we consider plasmatic Hcy a complication-risk indicator in type 1 DM, and we recommend its use together with already established biochemical parameters in the control of the evolution of the disease.
authors.affiliation: Servicio de Análisis Clínicos, Laboratorio de Bioquímica, Hospital Universitario Virgen de la Arrixaca, Ctra Madrid-Cartagena, 30120 El Palmar, Murcia, Spain. teresa.agullo@arrakis.es
authors.forename: M T
authors.initials: MT
authors.lastname: Agulló-Ortuño
authors.forename: M D
authors.initials: MD
authors.lastname: Albaladejo
authors.forename: S
authors.initials: S
authors.lastname: Parra
authors.forename: M
authors.initials: M
authors.lastname: Rodríguez-Manotas
authors.forename: M
authors.initials: M
authors.lastname: Fenollar
authors.forename: F
authors.initials: F
authors.lastname: Ruíz-Espejo
authors.forename: J
authors.initials: J
authors.lastname: Tebar
authors.forename: P
authors.initials: P
authors.lastname: Martínez
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications*; D003925:Diabetic Angiopathies / Q000097:blood / Q000453:epidemiology; D003928:Diabetic Nephropathies / Q000097:blood / Q000453:epidemiology; D003930:Diabetic Retinopathy / Q000097:blood / Q000453:epidemiology; D005260:Female; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012044:Regression Analysis
chemical_list: D015415:Biomarkers; D006710:Homocysteine